OpenNashPodcasts

The Long Run with Luke Timmerman

Ep87: Bob Nelsen of ARCH Venture Partners on Biotech Investing

1 Mar 2021 · 49m · Luke Timmerman, Bob Nelsen · 22 quoted facts

▶ Play episodeOriginal source ↗

In brief

Bob Nelsen argues that biotech investing should be driven by scientific and clinical impact rather than by returns, and that ARCH's new $1.85 billion Fund 11 follows that rule. He says the money is a tool, not the goal. The priorities he names are mental health, manufacturing, delivery of cell and gene therapies, and rejuvenation, with incremental products avoided.

The tension is scale. Large funds usually lose their edge or start just "putting money to work," so Nelsen describes ARCH's workarounds. These include "X" innovation divisions inside portfolio companies, raising the smallest round that attracts the best investors, and building Resilience as shared manufacturing. He admits the hardest bottleneck is great company builders, not capital, and that policy and market cycles could still hurt.

Key insights

  1. Talent, not capital, is the scarce resource

    Nelsen says the hardest thing is finding great managers and scientific innovators, not money. ARCH therefore incubates new ideas inside existing portfolio companies so the same builders can serve several projects.

  2. ARCH incubates companies inside existing companies

    Examples include Prime inside Beam, plus 'X' divisions at Sana and Resilience. The parent company may get a market-rate stake, while ARCH invests from another fund so the spinout stays independent.

  3. Mental health is framed as biotech's next frontier

    Nelsen calls it 'the problem of our time' and expects viruses and many cancers to become manageable. He says the brain is hardest because of the blood-brain barrier and unclear genetics, though genetic 'hooks' like APOE4 give a starting point.

  4. Resilience aims to industrialize cell and gene therapy

    Nelsen was frustrated by the slow pandemic response. He wants a TSMC-like, systematized manufacturer, drawing on how semiconductor investment made computing cheaper and faster, to replace proprietary, small-batch production at each university, biotech and pharma.

  5. Smaller rounds with the best investors win

    Nelsen says ARCH often spends a month trying to shrink a financing round, aiming to raise the least money from the best backers. He says the big headline rounds could have been larger, and that the best investors can add more later.

Questions

What is ARCH Venture Partners' Fund 11 and how big is it?

Host Luke Timmerman calls it a $1.85 billion fund for new biotech startups, which Bob Nelsen describes as covering everything from $50,000 early checks to roughly $250 million for big projects.

Why does Bob Nelsen think a huge fund won't ruin ARCH's early-stage approach?

He says the risk is real, since big funds often lose their edge or fixate on 'putting money to work.' He argues ARCH has handled both small and large deals in Funds 8, 9 and 10 by keeping the scientific bar high and judging deals by impact, not money.

What is Resilience, the manufacturing company Nelsen talks about?

It is a company ARCH backed to make cells, viral vectors (virus-based delivery vehicles for gene therapy) and gene edits faster, cheaper and more consistently. Nelsen wants it to be the obvious outsourced choice, the way TSMC is for chips.

Why does Nelsen favor surrogate endpoints in Alzheimer's and Parkinson's trials?

A surrogate endpoint is a measurable marker, such as blood pressure, used in place of waiting years for a clinical outcome like a heart attack. Nelsen says we already approve hypertension drugs this way, so five-to-ten-year trials for brain disease are unnecessary, and drugs can be pulled later if they fail.

How does Nelsen expect drug-pricing politics under the Biden administration to affect biotech?

He expects some 'crazy' pricing proposals in Congress but thinks most Democrats understand the value of US biotech innovation. He warns that attacks on pharma tend to cut funding for biotech, even though pharma needs to buy or partner for innovation.

Facts

Stated by the speakers. Each quote matches the transcript, which shows what was said, not that it is true.

ARCH Venture Partners' Fund 11 is described by host Luke Timmerman as a $1.85 billion fund for investing in new biotech startups.

“Now for this conversation, I focus mainly on what Bob and the Arch investing team want to do with the latest fund, Fund 11. It's a $1.85 billion colossus to invest in new biotech startups.”

0:01:10 · Luke Timmerman · Fund 11

Bob Nelsen was an early investor in Illumina, Alnylam, Juno and Vir, according to Luke Timmerman.

“He was an early investor in gene sequencing technology with Illumina, RNA interference with alnylam, cell therapy with Juno, and infectious disease with Vir.”

0:00:33 · Luke Timmerman · Past investments

Matthew Herper wrote a profile of Bob Nelsen for Forbes in 2016.

“Matt Herper wrote a nice profile of Bob for Forbes in 2016.”

0:01:44 · Luke Timmerman · Media profile · 2016

Luke Timmerman began covering biotech at the Seattle Times, where he met Bob Nelsen early in Nelsen's time at ARCH.

“He was one of the first people I met when starting out covering biotech at the Seattle Times.”

0:00:33 · Luke Timmerman · Host background

ARCH's Fund 11 press release said it would still write investments ranging from $50,000 to $250 million.

“But you mentioned that you're still going to do these $50 ,000 checks all the way up to $250 million, whatever the thing requires.”

0:06:02 · Luke Timmerman · Check sizes

Luke Timmerman says the Fund 11 press release lists infectious disease, mental health, immunology, oncology, neurology, manufacturing, clinical trials, anti-aging, genomic and biological tools, and data sciences among its areas.

“Infectious disease, mental health, immunology, oncology, neurology, manufacturing, clinical trials, anti-aging, genomic, biological tools, data sciences.”

0:13:07 · Luke Timmerman · Investment areas

Bob Nelsen cites Prime as a company incubated within Beam as an example of ARCH's company-within-company model.

“Well, I think an example would be that Prime is kind of has incubated within Beam.”

0:10:41 · Bob Nelsen · Incubation model

Bob Nelsen contrasts Flagship Pioneering's incubation of companies within Flagship with ARCH's model of incubating companies within existing portfolio companies.

“While Flagship might incubate companies, a bunch of companies within Flagship, we have a model that's kind of incubating companies within companies.”

0:10:41 · Bob Nelsen · Incubation model

Bob Nelsen says the Japanese government appointed a minister of loneliness, citing it amid concern about suicides in Japan.

“I think the Japanese government just appointed a minister of loneliness.”

0:15:03 · Bob Nelsen · Mental health · 2021

Bob Nelsen says people with two copies of the APOE4 gene variant, which he calls APOE44, are probably going to get Alzheimer's disease.

“We know if you have an APOE44, you're probably going to get it.”

0:18:20 · Bob Nelsen · Alzheimer's genetics

Bob Nelsen suggests cell therapy companies could run their own treatment centers next to hospitals, owned by the company that manufactures the cells.

“maybe you create a cell therapy center that sits next to a big hospital but it's it's you know essentially owned by the company that's manufacturing the cells.”

0:21:27 · Bob Nelsen · Healthcare delivery

Bob Nelsen argues the world's pandemic response was inadequate, noting it took about a year and roughly half a million deaths in the US to reach vaccines.

“It only took a year and a half a million dead people, right?”

0:23:30 · Bob Nelsen · COVID-19 response · 2021

Bob Nelsen says Resilience should become the obvious outsourcing choice for biologic manufacturing, using TSMC as a model.

“obvious that you should work with us versus doing it yourself and you know tsmc is a good model for that”

0:26:18 · Bob Nelsen · Resilience strategy

Bob Nelsen says the semiconductor industry's heavy investment in better, faster, cheaper manufacturing drove the entire computer industry, and biotech can learn from that.

“they actually invest a lot of money um and technology figuring out how to make stuff uh way better faster cheaper and that's what drove the entire computer industry”

0:26:18 · Bob Nelsen · Manufacturing

Bob Nelsen questions whether antibodies must be made in large steel tanks and suggests making them inside the body instead.

“Do we have to make antibodies in big giant steel tanks? Maybe we should make them in the body.”

0:27:13 · Bob Nelsen · Biomanufacturing

Bob Nelsen says an immortalized B cell could, in principle, supply all the vaccines a person would ever need.

“if I can make an immortalized B cell I could give you all of the vaccines you would ever need in your lifetime”

0:28:35 · Bob Nelsen · Cell therapy

Bob Nelsen says the biggest threat to the biotech industry was the drug-pricing agenda of Elizabeth Warren and Bernie Sanders, which he says did not come to pass.

“the big threat to the industry was the Elizabeth Warren crazy, Bernie Sanders crazy, you know, see crazy that, you know, don't really understand innovation is actually the solution to public health, not the problem.”

0:31:04 · Bob Nelsen · Drug pricing · 2021

Bob Nelsen argues that requiring five-to-ten-year trials instead of using surrogate endpoints for Alzheimer's and Parkinson's drugs is unreasonable.

“we can't, you know, develop intermediate markers for Alzheimer's or Parkinson's or, you know, other chronic and debilitating disease and that we have to have, you know, five or 10 year long clinical development cycles is just crazy.”

0:36:47 · Bob Nelsen · Surrogate endpoints

Bob Nelsen says ARCH typically spends about a month trying to reduce the size of a company's financing round to raise the minimum needed from the best investors.

“And almost certainly we spent like a month trying to cut back the size of the round.”

0:39:48 · Bob Nelsen · Funding rounds

Bob Nelsen says Sana Biotechnology's successful IPO as a preclinical company reflected investors who evaluated the data and long-term potential rather than short-term news flow.

“well, how is Sana so successful in their IPO being a preclinical company, right? It's because people actually looked at the data and thought about where they could be in five or ten years.”

0:41:50 · Bob Nelsen · Sana IPO · 2021

Bob Nelsen says ARCH has banned the phrase 'news flow' as part of its long-term, science-driven investing culture.

“Yeah, we banned the word news flow from Arch.”

0:42:25 · Bob Nelsen · ARCH culture

Bob Nelsen predicted the United States would reach herd immunity against COVID-19 before other major countries because of its strong vaccines and low mask compliance.

“the fact that we have the best vaccine and the stupidest group of people that don't wear masks will conspire together to have the U.S. reach herd immunity probably before any other major country.”

0:44:36 · Bob Nelsen · Herd immunity · 2021

Chapters

  1. 0:03:58Why Nelsen still loves the job

    Nelsen explains the motivation behind two decades of turning science into companies: working on big unsolved problems with brilliant people.

    “it's like the most fun job that you could have”
  2. 0:06:41Can a giant fund stay early-stage?

    Nelsen addresses the central risk of a $1.8B fund and why impact, not deploying capital, should drive decisions.

    “many funds that get big have lost their edge”
  3. 0:08:39X divisions and the human-capital bottleneck

    ARCH is experimenting with incubating new ventures inside portfolio companies because company builders, not cash, are scarce.

    “the biggest scarce resource right now is actually not capital. It's human capital.”
  4. 0:14:47Mental health and the brain as the next frontier

    Nelsen explains why the new fund prioritizes neuroscience and mental health after the pandemic.

    “it's kind of the problem of our time more than viruses and cancer and other things.”
  5. 0:22:16Healthcare delivery as a company-owned service

    Nelsen imagines cell therapies delivered through company-run centers rather than conventional hospital systems.

    “maybe there is no drug per se, it's kind of a service, right?”
  6. 0:25:42Resilience and rethinking biomanufacturing

    Nelsen lays out the case for systematized, shared manufacturing of cells, vectors and edits, borrowing lessons from semiconductors.

    “we want to be the best manufacturer of cells and genes and edits in the world.”
  7. 0:31:48Drug pricing politics and market cycles

    Nelsen predicts policy friction under Biden and eventual down cycles, while arguing pharma's need for innovation protects biotech.

    “when they go after pharma, it tends to drop the money for biotech.”
  8. 0:36:07FDA reform and surrogate endpoints

    The two discuss funding the FDA and using intermediate markers to speed development in chronic brain diseases.

    “We can't just think about clinical endpoints. We need to think about surrogate endpoints”
  9. 0:38:30Impact first, money second

    Nelsen describes ARCH's anti-transactional philosophy, including shrinking funding rounds and banning 'news flow.'

    “not thinking about the money is the way to make the most money.”

Transcript

0:00:01
Luke Timmerman

Welcome to the Long Run. This is a podcast for biotech adventurers. I'm your host, Luke Timmerman. Today's guest is Bob Nelsen. Bob is the co-founder and managing director of Arch Venture Partners. He's one of the most prolific and successful venture capitalists in biotech history. Bob likes to get involved in startups in the very early days. He's willing to stick his neck out and do things that might seem weird or premature to most people at the time.

0:00:33

He was an early investor in gene sequencing technology with Illumina, RNA interference with alnylam, cell therapy with Juno, and infectious disease with Vir. He dreams big, thinks ahead of the pack, and isn't afraid to take risk. I've interviewed Bob too many times to count over the past 20 years. He was one of the first people I met when starting out covering biotech at the Seattle Times. He was just getting established at Arch in those days. In 2016, when he made the Forbes Midas list, I wrote that he is Still true.

0:01:10

He's always been a character. Love him or hate him for whatever reason. Now for this conversation, I focus mainly on what Bob and the Arch investing team want to do with the latest fund, Fund 11. It's a $1.85 billion colossus to invest in new biotech startups. He talked about some priority indications for investment, including some new higher priorities coming out of the pandemic, especially mental health and biomanufacturing. I didn't ask Bob to cover his personal story in this conversation, as others have covered it before.

0:01:44

Matt Herper wrote a nice profile of Bob for Forbes in 2016. Now, before we dive in, a word from the sponsor of The Long Run, Synthego. Synthego is a genome engineering company that enables the acceleration of life science research and development in the pursuit of improved human health. The company leverages gene editing, machine learning, and automation to build platforms for science at scale. By enabling unprecedented access to cutting-edge genome engineering, Synthego is at the forefront of innovation, accelerating the development of truly engineered biology.

0:02:21

Synthego's expertise in CRISPR, combined with their proprietary software and technology, means you have a trusted partner, whether you are at early stages of basic research or ready to take your therapy to the clinic. Visit synthego.com slash Timmerman to learn more. And if you like listening to The Long Run, check out Timmerman Report. This is where you'll get my in-depth coverage of startups, biotech trends, and thought-provoking commentary from a diverse cast of contributing writers.

0:02:50

Go to TimmermanReport.com for details. Now, please join me and Bob Nelsen on The Long Run. Bob Nelsen, welcome to The Long Run. Hi. so bob uh i want you to know for straight away that this is not a family podcast so if you want to uh you know be as profane as you want to be it's totally fine yeah i was swearing on twitter

0:03:14
Bob Nelsen

a lot yesterday so it's a good chance i'll swear on this i've noticed does that mean you're in a good mood or a better mood than usual i tend to swear at the extremes good moods or bad moods

0:03:26
Luke Timmerman

Okay. Okay. Well, just for the listeners, I want to say starting off that I realize you and I have been talking about the same stuff basically for 20 years. Taking science and trying to turn it into businesses that create products that actually help people. And I don't know what that says about either one of us that we've been doing this this long, but it's kind of endlessly fascinating to me. Why do you think you still do it?

0:03:58
Bob Nelsen

I think it's just incredibly motivating to be, you know, with people that are way smarter than you all the time, trying to solve really, really big problems that are, you know, unsolved and have major impacts. So it's kind of a, to me, it's like the most fun job that you could have.

0:04:21
Luke Timmerman

Yeah, and biotech has just gotten so much more interesting over the years, don't you think?

0:04:30
Bob Nelsen

Yeah, I think we're just in this truly revolutionary, up and to the right kind of scientific and kind of even industrial innovation realm where a lot of vectors are kind of intersecting. that really will have just a fundamental impact on the human condition, you know, more than just human health or human maladies, but, you know, things like, you know, reversing aging and, you know, fixing depression and even thinking about optimizing kind of your mental state. human performance, those kind of things, you know, well beyond just, you know, fixing a malady

0:05:28
Luke Timmerman

like COVID. So let's talk about, I want to go into a number of those things, because you mentioned them in this really dense press release that you sent a couple weeks ago about your new fund, $1.8 billion fund, I think, 11. Is that right? Yeah. So I noticed right off the top that you mentioned that this is going to be for early stage company creation, the bread and butter, the stuff that Arch has done for 20 plus years.

0:06:02

But you mentioned that you're still going to do these $50 ,000 checks all the way up to $250 million, whatever the thing requires. And I wonder, now that you've been more successful in recent years, you've gotten some big returns, some big wins, you raise more money. Does that create something of a challenge for you to stay true to your roots, to do those three guys and a dog kind of startups that really only need $1 million?

0:06:34

Does that really even make sense in a fund this big? Or do you have to become something different like a growth equity kind of fund?

0:06:41
Bob Nelsen

I mean, that is the challenge. And so, you know, many funds that get big have lost their edge and they tend to either it's the kind of the old guys who have made most of the money handed off to other folks who don't know how to make money or don't know how to build companies. or it's they start thinking about what we would call putting the money to work, which is like a bad phrase in the arch.

0:07:12

It should just be about doing cool stuff and having impact. So if you can have impact with $1 million, that's awesome. If it takes 100 million to have impact, that's fine. And so some of the things we do, we couldn't have done, you know, Some things really do need $100 million or $200 million to have impact because you need scale and you need to invest and you need multiple things. And some things, you know, really do just need to be brought to the next technical risk reduction.

0:07:46
Luke Timmerman

um so do you think you um can do both the the early stage you know small companies and the the really big audacious plays like a resilience uh in the same fund yeah i think you know we've done

0:08:04
Bob Nelsen

it in um you know fund eight nine and ten so i think we'll be able to do it in 11 i think um and but you do have to you do have to kind of just keep the scientific bar high that's really the the key thing is is to just keep that love of the scientific innovation one of the things that we're doing to innovate within the innovation model is starting to incubate some of these smaller things within the companies we already have.

0:08:39

Because the biggest scarce resource right now is actually not capital. It's human capital. It's great managers. It's great company builders. It's great scientific innovators within companies. And that is actually the hardest thing. So we're We're doing a bunch of companies where we're actually in, we kind of create these innovation divisions within a company like sauna has sauna X resilience has resilience X. And those X divisions are meant to be kind of the R and D innovation, high risk, high risk money.

0:09:20

And, and we can take a new idea incubate it within those companies and actually invest in it from the other fund, not have it be controlled by the company. It can be a completely independent company. And then kind of in exchange for being incubated, it might give a pick or two, a market rate kind of pick or two to the company that's incubating it. So we're experimenting with this model to be able to do more things and also be able to be more effective at company building because we've just found that the biggest risk that we have is picking the wrong people and trying to build these teams over and over.

0:10:06

And when every graduate student with a new paper thinks that they have a new company, you really need to figure out a way to not build a thousand different companies because you're sub-optimizing. It's really interesting. We're experimenting.

0:10:23
Luke Timmerman

Is there a historical analogy here? I'm trying to think of like a past Arch investment, like something like, say, Agios, you know, where you bet on a founder and then, you know, he brings in some people around him, like I say, a John Evans, who, you know, gets to work and learn a whole bunch of cool new things. And then eventually, you know, out he comes to join Arch and start Beam.

0:10:41
Bob Nelsen

Well, I think an example would be that Prime is kind of has incubated within Beam. And we have other, you know, companies that are unannounced that are incubating within some of our other companies. So while Flagship might incubate companies, a bunch of companies within Flagship, we have a model that's kind of incubating companies within companies. And then we still have our conventional model that is incubating just new companies and doing kind of the classic venture model.

0:11:15

Okay, but this is a little bit of both.

0:11:18
Luke Timmerman

This is a way for you to scale a bit without building a whole bunch of new infrastructure at Arch.

0:11:24
Bob Nelsen

It's not even scale per se. It's more just efficient allocation of human capital, right? There aren't that many great company builders out there. So when you find one or multiple of them, the amount of effort that it takes into building that first year one or year two team is immense. If you can apply some of that human capital across, you know, kind of multiple projects and they can handle it. And that's how we've done it within these X divisions is really build the X division to be, you know, kind of great early stage risk reducers.

0:12:14

Right.

0:12:15
Luke Timmerman

But is this a place where company builders are made? because they're not necessarily born and they don't just like present themselves with a great resume to you and it's like obvious like bob you should fund this guy out of mit like they need to

0:12:28
Bob Nelsen

learn somewhere right yeah i don't think we've proven that we can make them there but we definitely are excited about um reducing the risk you know in that context right where we're reducing saying technical risk within these kind of X divisions or within companies within the X divisions, and then decide whether these are independent companies that we should put a lot of money in later. And so that's one of the innovation models that we're playing with.

0:13:07
Luke Timmerman

Let me ask you a little bit about this fund, though. You got $1.8 billion. It's a lot of money. I mean, maybe not in the grand scheme of things, like how much money people put into things like Uber and whatever. I mean, but you've got $1.8 billion. There's a lot of things you can do with it, places you can put it. I mean, you list something like 11 different categories in your press release. Infectious disease, mental health, immunology, oncology, neurology, manufacturing, clinical trials, anti-aging, genomic, biological tools, data sciences.

0:13:41

and then new ways of reimagining diagnostics and therapies. There's a lot there. How did you come up with that list? And maybe like, why did those things get on there? And what were some things you left off?

0:13:54
Bob Nelsen

I just think it's a following the science list, right? And following the clinical or kind of market need. You know, clinical trials need to be reinvented. Manufacturing is a huge issue. You know, we think the frontiers of science will go into kind of in vivo gene therapy and in vivo potentiation of cell state, you know, rejuvenation of cells, organs, people, things like that. But there's, so some of it is kind of, and then in the mental health area, it's, you know, nobody needs explaining, you know, kind of why mental health is a problem.

0:14:47

I think it's kind of the problem of our time more than viruses and cancer and other things.

0:14:54
Luke Timmerman

Well, it was there and it was big before the pandemic. But now, I mean, doesn't this look like, I mean, just a huge iceberg coming out of it?

0:15:03
Bob Nelsen

I was looking at this epidemic of suicides in Japan. I mean, there's just, I think the Japanese government just appointed a minister of loneliness. you know sounds like the Trump post-presidency or something but but basically I think it's it's this viruses will be handleable you know the next pandemics I think will be prepared. The science isn't the hardest science. And it's a lot more about, you know, some pretty good R &D and a lot of engineering and scale.

0:15:53

So I actually think viruses will be handleable. I I think cancer will be a lot either prevented, you know, with early detection or treatable. So, you know, you start kind of going down the list and then you get into the hard ones and they're mostly in the neurospace of Alzheimer's, Parkinson's, mental health, really hard. And then when you think about rejuvenation and, you know, kind of reconditioning the body, then you can think about liver and kidney and, and heart.

0:16:31

And, and, you know, then those are kind of the next frontier with the brain being obviously the most complicated, both to excess, you know, from a kind of blood brain barrier, protected status, and, and also to even understand from either a genetic, a circuit, or kind of phenotypic level. So I think there's a lot of redefining of the existing paradigms that need to be done to really kind of fix the brain.

0:17:15
Luke Timmerman

Do you think, Bob, that the neurodegeneration and some of that mental health stuff, is that ripe or mature for venture investment? Or is this an area where a lot of the basic biology, like NIH funds, needs to be allocated and worked out?

0:17:33
Bob Nelsen

I think it's both. I think you can approach mental health from what I would say is the soft side of it, right? In terms of things that you can do to make you feel better. and then you can approach it from the hard science which is really the kind of the genetics and the quantitative phenotyping and you know the the real biology that's going on that drives you know a mental illness or something you know neuroinflammation that something that might drive a disease or, you know, whenever we figure out what drives Alzheimer's.

0:18:20

So some of it is risky science. Alzheimer's to be the perfect example of that. At the same time, there is a hook in Alzheimer's, right? We know if you have an APOE44, you're probably going to get it. So that's huge, right? We know that there's, you know, at least you're going to get it in the definition of what it is so in other words alzheimer's might be more than one probably is likely more than one disease um so at least that version of the disease you get if you have apoe4-4 and so so there are these hooks that you that you have so it's not like totally in the dark um and the same thing with mental health some

0:19:07

things are very specifically genetic and some things are polygenic and it's just hard to figure out you know the weights and and how you look at it but you know it's it's you know uh linked um and some things we don't really know much about and and you can get into the very soft areas you know like how do you feel you know state of consciousness type of things but you know there there are some digital therapeutics and ways to kind of manipulate brain chemistry to make you happier which is you know ultimately where we want to get right which is we all want to be happier and more productive and you know that that kind of and and in

0:19:52

an ideal world we'll be happier more productive and rejuvenated and younger and, you know, without disease for a longer period of time. Or if you have a disease, we'll be able to fix it. So I think we're really in that realm. Within our lifetimes, you'll be able to fix a lot of these things.

0:20:16
Luke Timmerman

Synthego is a genome engineering company that enables the acceleration of life science research and development in the pursuit of improved human health. The company leverages gene editing, machine learning, and automation to build platforms for science at scale. By enabling unprecedented access to cutting-edge genome engineering, Synthego is at the forefront of innovation, accelerating the development of truly engineered biology. Synthego's expertise in CRISPR, combined with their proprietary software and technology, means you have a trusted partner whether you are at early stages of basic research or ready to take your therapy to the clinic.

0:20:51

Visit synthego.com slash Timmerman to learn more. Another thing that I noticed in your plan for your new fund is that you talk about healthcare delivery. And I haven't heard you talk as much about this in the past, things like how data gets collected, how therapeutics get manufactured, and ultimately where the rubber meets the road, where the care gets delivered to the patient. What kind of investment opportunities do you see there kind of extending upon your foundation?

0:21:24

I think it's, you know, the biggest

0:21:27
Bob Nelsen

one when we think about delivery there is mental health. But you can imagine in gene therapy or cell therapy, if you have high impact therapeutics that are, let's say you have, you know, things that are the cure solid tumors you know do you just have to go to the existing system with your cell therapy that cure solid tumors or maybe you create a cell therapy center that sits next to a big hospital but it's it's you know essentially owned by the company that's manufacturing the cells.

0:22:16

So you can imagine as these complex biologics whose manufacturing is connected to the function of the therapeutic, you know, maybe there is no drug per se, it's kind of a service, right? You, you know, you want, you have cancer, you come in, we'll cure your cancer by giving you the cells. But you don't have to go to Stanford to get your cancer cured.

0:22:48
Luke Timmerman

You're going to that partner with Stanford that's across the street.

0:22:52
Bob Nelsen

We might partner with Stanford in a situation like that. Because, you know, things might, you know, there's like reasons to go to the hospital, but, you know, getting your cancer cured might not be a reason to go to the hospital. Okay, so that is healthcare delivery.

0:23:12
Luke Timmerman

you mentioned also manufacturing you've got this big play here with resilience and I know that this one came out of your ruminations on one of the big gaps you've seen during the pandemic well where did this idea come from what are you trying to accomplish with it pretty much what you said

0:23:30
Bob Nelsen

I mean, it's just me being pissed off at observing the inability of our world to respond to the pandemic. And, you know, we did a great job in some context, right? It only took a year and a half a million dead people, right? So it's like, I'm not satisfied that we should be patting ourselves on the back and saying like, oh, this is great. um and so um you know i think that we can do things faster better cheaper more effectively um more predictable anticipating the next uh problems and at the same time you know solve many of the problems in gene therapy and cell therapy gene editing that make them very kind of unpredictable, hard to manufacture and regulate

0:24:31

and, um, and riskier, uh, you know, you can systematize all of those things and make them a lot cheaper at the same time. So more accessible, um, and, you know, more consistent, decentralized data-driven, um, therapeutics, versus the existing system that we live in right now, which is, you know, shit happens in CMC, shit happens in clinical trials. You know, there's, it's just a messy kind of first inning, kind of, we're in the first inning and we just have never really invested in systematizing cells or viral vectors or editing.

0:25:23

Instead, everybody's got their own proprietary,

0:25:25
Luke Timmerman

They got their own proprietary thing and they do it in small batches.

0:25:29
Bob Nelsen

And, you know, and then every university has one and every biotech has one, every pharma has one.

0:25:35
Luke Timmerman

So, but you're, you're thinking of like a go-to resource where these are the guys that make, you know, AV vectors at scale.

0:25:42
Bob Nelsen

And we want to be the best manufacturer of cells and genes and edits in the world.

0:25:48
Luke Timmerman

The nanoparticles, it's like, you know, an mRNA vaccine comes along.

0:25:53
Bob Nelsen

Yeah, better than any one company.

0:25:56
Luke Timmerman

It's all under one roof, although that roof is distributed across North America. But it's a place where people work out the processes to make the absolute best, fastest, cheapest AAVs. Like, oh, you need to make a billion AAV vectors in the next three to six months? This will be the place to do that.

0:26:18
Bob Nelsen

yeah we want to be we want to be obvious that you should work with us versus doing it yourself and you know tsmc is a good model for that but but um you know the the general idea is we we can learn some things from semiconductors in the sense that they actually invest a lot of money um and technology figuring out how to make stuff uh way better faster cheaper and that's what drove the entire computer industry right yep and so if you can systematize more about the biology um whether it's automating cell therapy or whether it's uh kind of being able to make rapid cell lines or scale viral vectors faster.

0:27:13

You know, you can have just a more effective system. And then if you take a step back and go into the basic biology, then you can rethink how these things should be made. And that's where it takes some basic R &D instead of applied R &D, really thinking about, wow, are we even making these things the right way? Do we have to make antibodies in big giant steel tanks? Maybe we should make them in the body.

0:27:49
Luke Timmerman

Well, we're already doing that with mRNA.

0:27:51
Bob Nelsen

Well, I mean, your body is making antibodies all the time without mRNA, right? So, you know, there are some really interesting ways of thinking about or rethinking the way that things are made. And, you know, mRNA is a great example, but there are many others.

0:28:19
Luke Timmerman

but I hear what you're saying like you could take some basic biology people out of academia who haven't even really thought that much about what's the best, fastest, cheapest way to make antibodies, you give them a company that's got some resources they can go to work on rethinking that part as opposed to some other

0:28:35
Bob Nelsen

if I can make, just to give you an example if I can make an immortalized B cell I could give you all of the vaccines you would ever need in your lifetime and you know correct any, you know, anything you, anything else you happen to need at the time. And probably a hundred cells.

0:29:01
Luke Timmerman

So they'll just be stored somewhere in case or, yeah, or just,

0:29:05
Bob Nelsen

and maybe I just give them to you, you know, if I'm in, if you're in Africa and I just encounter you once, I can just give you a hundred cells that have all the things that you need and that's it.

0:29:19
Luke Timmerman

Wow, that's pretty cool.

0:29:21
Bob Nelsen

That obviously would change the supply chain of a lot of different things. And if you're selling a lot of Rituxan or Septin or whomever, I don't know, pick your drug. those technologies work pretty well but they're expensive and inefficient relative to your body's ability to make stuff so one way or another I think you'll see some kind of major changes in the way that things are made or at least

0:30:09
Luke Timmerman

some things are made. Yeah, that manufacturing piece has been neglected for so long. And there's a lot of room for innovation. This is a longer conversation. I want to have another day. But I do want to ask you as well, sticking to this new fund, you know, you have to be looking at a whole lot of the macro shit that's gone on in this shit show of a year with COVID-19. And, you know, do you see like really big changes to the investing landscape?

0:30:39

I mean, whether it's, you know, are we going to ever get universal coverage in the United States coming out of, you know, pandemic that, you know, affected a whole lot of people in different ways? Are we going to fund public health to a greater degree, both at the federal and state and local level? You know, what about NIH? How does this like change the way you think about what you do? and invest.

0:31:04
Bob Nelsen

I think that, you know, I've said this before, the big threat to the industry was the Elizabeth Warren crazy, Bernie Sanders crazy, you know, see crazy that, you know, don't really understand innovation is actually the solution to public health, not the problem. And, you know, governments don't create those solutions. Private industry does. So the solution. Those things didn't happen. Yeah. So those things didn't happen. I think the Biden administration, you'll see some, you know, crazy drug pricing proposals in Congress, you know, maybe something accidentally that, you know, that sweeps up innovation gets through.

0:31:48

But I think the, you know, the most of the Democrats in the Senate and the Biden administration understand that the innovation infrastructure is not just an American, you know, dominant area in biotech, but one that creates a lot of jobs and has the promise of making things more accessible, better, faster, cheaper, and curing stuff, you know, instead of spending lots of money on hospitals and things. So ultimately, I think that view will prevail. That doesn't mean there's some two steps forward, one step back piece of this, because what happens is when they go after pharma, it tends to drop the money for biotech.

0:32:40

So I think that we will, and we're not going to be in the kind of public markets we're in right now forever. There just are going to be cycles. So ultimately, there will be this, I don't think it's going to be feast famine kind of thing, but there will be down cycles. And there will be too many companies and there'll be some right sizing. And, you know, pharma will get, pharma, I think, is under threat from lots of different angles.

0:33:16

So pharma needs to kind of innovate or be in trouble. And frankly, since they can't really innovate, they have to buy that innovation or partner that innovation. So even in a down cycle where pharma is the target, that makes our more innovative companies more valuable.

0:33:40
Luke Timmerman

Well, I think right now pharma might be getting a little bit of a break on the drug pricing thing. I mean, they were at the bottom of the barrel on reputation at the beginning of this pandemic. And now some polls are showing that people are starting to think pharma, maybe not as bad as we once thought. So, you know, maybe that, you know, falls under the header of, you know, what you and a lot of your colleagues in the industry say to government, which is basically, you know, don't kill us.

0:34:05

Don't hurt us. But, you know, I wonder if you think about the other side of the coin, too, like because there is this mood for more bold thinking. You know, Janet Yellen and, you know, these others are talking about like the risk of doing too little. And, you know, you appreciate as well as anybody else, like the catalytic role that government can play, like with investing in, say, basic research, for instance. Do you think there's an opportunity here to like, you know, really press on the gas and like, you know, hold on to competitive advantage in the United States and, you know, create a whole lot of new, I mean, arches and companies that do more amazing things?

0:34:40
Bob Nelsen

I think investing in basic research is always a good thing. And so increasing basic research investment is, you know, an awesome thing. And I think that that probably will happen in this environment. And so I also think that regulatory reform, and you don't have to use the word reform, just having the FDA be well-funded enough that it can kind of join the next generation of technology and embrace it. because it's actually going to make their life much easier because it's, it's a, you know, kind of a data driven, more systematic world, which is the thing, you know, you go work at the FDA because you like data and, and you want things to be controllable and systematic.

0:35:40

And so when you think about the, the world we live in right now and cell therapy and gene therapy, right, It's not controlled and systematic, and that's a risk, right?

0:35:53
Luke Timmerman

Well, I think FDA needs more resources to put in place the data science infrastructure, the adaptive trial infrastructure, be able to hire the people, like staff up in the cell and gene therapy reviews, because otherwise there's going to be a big bottleneck.

0:36:07
Bob Nelsen

Yeah, I think that's true. And I think it's also, you know, even in places like CNS, I mean, we do need some reform in thinking there. right? We can't just think about clinical endpoints. We need to think about surrogate endpoints when you're thinking about Alzheimer's and Parkinson's and some of these other things. And, you know, people are like, oh, you know, that's risky. We can't do surrogate endpoints. And, you know, it's kind of like, really, you know, what's hypertension?

0:36:43
Luke Timmerman

It's a risk factor for heart attack and stroke. That's right.

0:36:47
Bob Nelsen

It's a surrogate endpoint. We develop drugs all day long for hypertension. So this idea that we can't, you know, develop intermediate markers for Alzheimer's or Parkinson's or, you know, other chronic and debilitating disease and that we have to have, you know, five or 10 year long clinical development cycles is just crazy. Yeah, I don't have a big problem with surrogates. So we do need to rethink that.

0:37:19
Luke Timmerman

You know, and if when a drug fails to pan out on the harder end point later on, you can take the drug off the market or strip away that indication.

0:37:27
Bob Nelsen

Absolutely. It's the same thing even today with COVID. You know, why isn't J &J's vaccine out there now? We can do a phase four trial. And if it's nasty, then we can pull it off. But right now we're waiting two months after they have data to like have an inevitable approval.

0:37:47
Luke Timmerman

Well, it's coming, but they're supply constrained at the moment.

0:37:50
Bob Nelsen

Yeah. And we're pretending, you know, that all this kind of stuff, it doesn't matter what the supply chain is, you know, it's just a million doses. It's a million people, right? So I just think that we need to have a different, we need to take the COVID sense of urgency, and that should be everyday life. Yeah, I would personally take that. When it comes to drug discovery.

0:38:13
Luke Timmerman

I'd take that J &J vaccine today if I could get it. Okay. Hey, Bob, I know we're almost out of time, but is there some area of investing that you really want to stay away from in biotech that you think is a fad or not quite ready for prime time? That's something that's not on your list for this fund.

0:38:30
Bob Nelsen

I just think anything incremental. So we're just not really interested in things that don't have some disease modifying outcome. So I guess we're really focused on things that are trying to make a large clinical impact. And we don't really think about the money when we invest. And it turns out not thinking about the money is the way to make the most money. But you can't think about it like that. So you have to think about having the most impact and having the best science.

0:39:12

and then not thinking about the money and taking the risk. And then that's the way actually to make the most amount of money. But you can't think about making the most amount of money when you're thinking about the long-term science and the clinical impact or it screws up your decision-making.

0:39:32
Luke Timmerman

It almost is a new twist on the old George Merck saying, isn't it? Like, do something awesome to help patients. I'm paraphrasing here. and you'll make profits. You'll do okay. And the better you do, the more the profits will be.

0:39:48
Bob Nelsen

Yeah, it is. It's absolutely true. And he was right on. And I think it's the same thing with transact. We don't like transactional kind of deals. So everybody's like, okay, you just raised a lot of money for that company. It's the biggest round ever, whatever. And almost certainly we spent like a month trying to cut back the size of the round. So we're trying, like when we're raising money for sauna or resilience, we're trying to raise the minimum amount of money that we can raise to get the best investors in.

0:40:18

And it turns out those investors have a lot of money. So you kind of end up raising a lot of money. But the goal was not to raise a lot of money. The goal was to just get the best investors in and raise the least amount of money. And so all of those giant rounds that we're announcing could have been like way, way bigger. but it wasn't the right thing to do because, you know, you really just want to raise the least amount of money with the best people because you can always get more money from those people if you need it.

0:40:52
Luke Timmerman

Yeah. Money is a, as a tool to achieve the objective, right? I mean, it's, I don't look at a press release in a headline and say, you get, well, gee, Bob raised more money than this other guy down the street. Therefore, he's smarter or more successful. I mean, to an extent, yes. I mean, people have confidence in you because of your track record. But no, it's about like how many new drugs that you can come up with or how many patients that you can affect.

0:41:19

I mean, right?

0:41:21
Bob Nelsen

Right. Yeah. And I think it's one of those things where you, there are a lot of people in the business that are more transactional and that's where you just have to, you know, you can try to copy the phenotype, but if you're, you don't have a science driven long-term company, you know, you don't. Right. So you can, so I think that it's harder to tell these when the markets are hot, it's hard to tell the difference.

0:41:50

But, you know, Some investors can tell the difference. And people are saying, well, how is Sana so successful in their IPO being a preclinical company, right? It's because people actually looked at the data and thought about where they could be in five or ten years. And those are the kind of people that drove that. And it's not the kind of people that were saying, what's your news flow in Q2?

0:42:19
Luke Timmerman

Right. Right. Because, you know, if that's how you think, you're not going to make these bets at all in the first place.

0:42:25
Bob Nelsen

Yeah, we banned the word news flow from Arch.

0:42:31
Luke Timmerman

Last thing I want to ask you, Bob, what's one good book you've read lately?

0:42:36
Bob Nelsen

I haven't read a book since the pandemic. Really? No, not a single book since the pandemic. I've just been starting companies and being online and reading. I read a ton, but I just read online sources.

0:42:55
Luke Timmerman

Well, what's a good go-to source? Maybe one that might surprise people that you really gain insight from.

0:43:01
Bob Nelsen

I have no like go-to. I'm all over the place. I'm literally like just following. When I'm bored, I'm just Googling words and following any interesting thing that I find. I don't know. I was Googling lots of stuff about Africa and cloning rhinos yesterday. And who knows? I'm just all over the place.

0:43:36
Luke Timmerman

You're still curious. And you're still optimistic. how do you like foster that or maintain it? Cause I mean, there must've been some really shitty low days. I mean, there has been for everybody, right?

0:43:47
Bob Nelsen

I think it's just an innate state. You know, I'm, I've always been optimistic. I think if you're a seed venture capitalist, you have to be optimistic and otherwise you couldn't get up in the morning. The risks are too big and the problems are too many. So you have to have an innate sense of being able to kind of fix things and, you know, have a positive outcome eventually, even though every day there's some kind of fire to put out.

0:44:22

And, you know, if you've been doing it for as long as I've been doing it, you know that there's always going to be a fire to put out and it's probably manageable.

0:44:32
Luke Timmerman

Yeah. Yeah. Are you still long on America?

0:44:36
Bob Nelsen

Oh, yeah. I think I think we're going to be fine. I think ironically, I tweeted this yesterday, but ironically, the fact that we have the best vaccine and the stupidest group of people that don't wear masks will conspire together to have the U.S. reach herd immunity probably before any other major country. So all the countries that are making fun of us that are, you know, shut down, right, and have closed their borders, will still be searching for herd immunity, you know, six months from now, and we'll kind of have it and we'll be open.

0:45:14
Luke Timmerman

So our simultaneous genius and idiocy is the secret to our success.

0:45:19
Bob Nelsen

Yeah, that's what I was saying yesterday. It is a combination of innovation and idiocy that have led us accidentally, but the cost is half a million people, and who knows what long-term morbidities, and that lays at the feet of not really, I think, actually, some are society, but more are leadership. um and um and so i think that um there's a lot of learnings obviously from this but i do think that we're going to be okay and um and you know cities will be reinvigorated and you know there will be a spike in crime and things like that and then there will be a reaction to that just like there was in the 70s and 80s and you know

0:46:10

the society is not going to fall apart

0:46:15
Luke Timmerman

america the land of the genius and geniuses and home of the idiots

0:46:21
Bob Nelsen

but you know the the amazing thing is that like when it comes down to it like people care about their local communities they care about these things and you know once you don't hear all this bullshit on twitter every day you know you realize that there are you know the the common elements amongst the left and the right in the country are actually larger than people think.

0:46:42
Luke Timmerman

I actually do agree. It doesn't seem like it if you're on Twitter or these other kind of, you know, extreme polarizing sites,

0:46:49
Bob Nelsen

but people care about their kids and their families and their schools and their jobs and where things are going to go. And, you know, how are they going to take care of people? And, you know, they, those, those things are mostly universal across and they, frankly, in the U S people really do believe in the individual. Even if you, you know, kind of listen to the AOC or whatever, you know, this is like, you know, AOC is like the classic political entrepreneur driven by the individual, even though they're preaching a different ideology, you know, that is a socialist ideology that the irony is like the, you know, they could only do that here, you know, it's much harder to do

0:47:40

in a, in a, to come from nowhere and, you know, come up, you know, even in Europe, it's, it's kind of harder. So I think the U S is still a pretty special place and we'll rediscover that, you know, hopefully through a set of at least a couple boring years.

0:48:02
Luke Timmerman

We do still have a democracy and we're going to, I think, begin to start listening to each other and, you know, taking bits and pieces of everybody's ideas and putting them to work toward solving actual problems. I mean, we, we haven't, we haven't done it for a while, but I, I, I definitely see that same thing out there. My friends on the left and the right, you know, that we, We'll find a way to talk to each other again and start agreeing on things like let's beef up the NIH, the CDC, and the FDA, for instance, because they do important things.

0:48:36

And they enable companies like Moderna to come up here. That doesn't really just happen by accident. It doesn't happen in other countries, not to the same extent that it does here. Cool. Well, thanks so much, Bob. Thanks for joining me today on The Long Run. Thank you. Thanks for listening to The Long Run, a production of Timmerman Report. Pedro Rosado of Headstepper Media was a sound editor. Music is from D.A. Wallach. See you next episode.